Global Retinal Drugs Market 2018-2022

網膜用治療薬の世界市場2018-2022

◆タイトル:Global Retinal Drugs Market 2018-2022
◆商品コード:IRTNTR22469
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年4月16日
◆ページ数:133
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:Healthcare and Life Sciences
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、網膜用治療薬の世界市場について調査・分析し、市場概要、市場環境、網膜用治療薬市場規模、症状別(MD薬、DED薬、その他)分析、薬物クラス別(抗VEGF剤、コルチコステロイド、その他)分析、市場動向、競争環境、主要地域別市場規模(アメリカ、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・網膜用治療薬の世界市場概要
・網膜用治療薬の世界市場環境
・網膜用治療薬の世界市場動向
・網膜用治療薬の世界市場規模
・網膜用治療薬の世界市場:業界構造分析
・網膜用治療薬の世界市場:症状別(MD薬、DED薬、その他)
・網膜用治療薬の世界市場:薬物クラス別(抗VEGF剤、コルチコステロイド、その他)
・網膜用治療薬の世界市場:地域別市場規模・分析
・網膜用治療薬のアメリカ市場規模・予測
・網膜用治療薬のヨーロッパ市場規模・予測
・網膜用治療薬のアジア市場規模・予測
・網膜用治療薬の主要国分析
・網膜用治療薬の世界市場:意思決定フレームワーク
・網膜用治療薬の世界市場:成長要因、課題
・網膜用治療薬の世界市場:競争環境
・網膜用治療薬の世界市場:関連企業情報(ベンダー分析)

About Retinal Drugs

Retinal drugs are the medications that are used for the treatment of retinal diseases.

Technavio’s analysts forecast the global retinal drugs market to grow at a CAGR of 7.63% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the global retinal drugs market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Retinal Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• ALLERGAN
• Bayer
• F. Hoffmann-La Roche
• Novartis
• Regeneron Pharmaceuticals
• Valeant Pharmaceuticals

Market driver
• Rise in the prevalence of retinal diseases
• For a full, detailed list, view our report

Market challenge
• High cost associated with retinal disease therapy
• For a full, detailed list, view our report

Market trend
• Development of innovative therapies
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY INDICATION
• Segmentation by indication
• Comparison by indication
• MD drugs
• DED drugs
• Others
• Market opportunity by indication
PART 08: MARKET SEGMENTATION BY DRUG CLASS
• Segmentation by drug class
• Anti-VEGF agents
• Corticosteroids
• Others
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Retinal drugs market in Americas
• Retinal drugs market in EMEA
• Retinal drugs market in APAC
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Development of innovative therapies
• Rise in demand for sustained-release ocular formulations
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS0
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALLERGAN
• Bayer
• F. Hoffmann-La Roche
• Novartis
• Regeneron Pharmaceuticals
• Valeant Pharmaceuticals
PART 16: APPENDIX
• List of abbreviations
• Exhibit 01: Parent market
• Exhibit 02: Global ophthalmic drugs market segmentation
• Exhibit 03: Market characteristics
• Exhibit 04: Market segments
• Exhibit 05: Market definition – Inclusions and exclusions checklist
• Exhibit 06: Market size 2017
• Exhibit 07: Validation techniques employed for market sizing 2017
• Exhibit 08: Global retinal drugs market – Market size and forecast 2017-2022 ($ mn)
• Exhibit 09: Global retinal drugs market – Year-over-year growth 2018-2022 (%)
• Exhibit 10: Five forces analysis 2017
• Exhibit 11: Five forces analysis 2022
• Exhibit 12: Bargaining power of buyers
• Exhibit 13: Bargaining power of suppliers
• Exhibit 14: Threat of new entrants
• Exhibit 15: Threat of substitutes
• Exhibit 16: Threat of rivalry
• Exhibit 17: Market condition – Five forces 2017
• Exhibit 18: Global retinal drugs market – Market share by indication 2017-2022 (%)
• Exhibit 19: Comparison by indication
• Exhibit 20: Global MD drugs market – Market size and forecast 2017-2022 ($ mn)
• Exhibit 21: Global MD drugs market – Year-over-year growth 2018-2022 (%)
• Exhibit 22: Global DED drugs market – Market size and forecast 2017-2022 ($ mn)
• Exhibit 23: Global DED drugs market – Year-over-year growth 2018-2022 (%)
• Exhibit 24: Global other retinal diseases drugs market – Market size and forecast 2017-2022 ($ mn)
• Exhibit 25: Global other retinal diseases drugs market – Year-over-year growth 2018-2022 (%)
• Exhibit 26: Market opportunity by indication
• Exhibit 27: Global retinal drugs market share by drug class 2017 (%)
• Exhibit 28: Major anti-VEGF agents approved in the market
• Exhibit 29: Major corticosteroids approved in the market
• Exhibit 30: Customer landscape
• Exhibit 31: Global retinal drugs market – Market share by geography 2017-2022 (%)
• Exhibit 32: Regional comparison
• Exhibit 33: Retinal drugs market in Americas – Market size and forecast 2017-2022 ($ mn)
• Exhibit 34: Retinal drugs market in Americas – Year-over-year growth 2018-2022 (%)
• Exhibit 35: Top 3 countries in Americas
• Exhibit 36: Retinal drugs market in EMEA – Market size and forecast 2017-2022 ($ mn)
• Exhibit 37: Retinal drugs market in EMEA – Year-over-year growth 2018-2022 (%)
• Exhibit 38: Top 3 countries in EMEA
• Exhibit 39: Retinal drugs market in APAC – Market size and forecast 2017-2022 ($ mn)
• Exhibit 40: Retinal drugs market in APAC – Year-over-year growth 2018-2022 (%)
• Exhibit 41: Top 3 countries in APAC
• Exhibit 42: Market opportunity
• Exhibit 43: Vendor landscape
• Exhibit 44: Landscape disruption
• Exhibit 45: Vendors covered
• Exhibit 46: Vendor classification
• Exhibit 47: Market positioning of vendors
• Exhibit 48: ALLERGAN – Overview
• Exhibit 49: ALLERGAN – Business segments
• Exhibit 50: ALLERGAN – Organizational developments
• Exhibit 51: ALLERGAN – Geographic focus
• Exhibit 52: ALLERGAN – Segment focus
• Exhibit 53: ALLERGAN – Key offering
• Exhibit 54: ALLERGAN – Key customers
• Exhibit 55: Bayer – Overview
• Exhibit 56: Bayer – Business segments
• Exhibit 57: Bayer – Organizational developments
• Exhibit 58: Bayer – Geographic focus
• Exhibit 59: Bayer – Segment focus
• Exhibit 60: Bayer – Key offerings
• Exhibit 61: Bayer – Key customers
• Exhibit 62: F. Hoffmann-La Roche – Overview
• Exhibit 63: F. Hoffmann-La Roche – Business segments
• Exhibit 64: F. Hoffmann-La Roche – Organizational developments
• Exhibit 65: F. Hoffmann-La Roche – Geographic focus
• Exhibit 66: F. Hoffmann-La Roche – Segment focus
• Exhibit 67: F. Hoffmann-La Roche – Key offerings
• Exhibit 68: F. Hoffmann-La Roche – Key customers
• Exhibit 69: Novartis – Overview
• Exhibit 70: Novartis – Business segments
• Exhibit 71: Novartis – Organizational developments
• Exhibit 72: Novartis – Geographic focus
• Exhibit 73: Novartis – Segment focus
• Exhibit 74: Novartis – Key offerings
• Exhibit 75: Novartis – Key customers
• Exhibit 76: Regeneron Pharmaceuticals – Overview
• Exhibit 77: Regeneron Pharmaceuticals – Business segments
• Exhibit 78: Regeneron Pharmaceuticals – Organizational developments
• Exhibit 79: Regeneron Pharmaceuticals – Geographic focus
• Exhibit 80: Regeneron Pharmaceuticals – Segment focus
• Exhibit 81: Regeneron Pharmaceuticals – Key offerings
• Exhibit 82: Regeneron Pharmaceuticals – Key customers
• Exhibit 83: Valeant Pharmaceuticals – Overview
• Exhibit 84: Valeant Pharmaceuticals – Business segments
• Exhibit 85: Valeant Pharmaceuticals – Organizational developments
• Exhibit 86: Valeant Pharmaceuticals – Geographic focus
• Exhibit 87: Valeant Pharmaceuticals – Segment focus
• Exhibit 88: Valeant Pharmaceuticals – Key offerings
• Exhibit 89: Valeant Pharmaceuticals – Key customers



【掲載企業】

ALLERGAN, Bayer, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, and Valeant Pharmaceuticals.

★調査レポート[網膜用治療薬の世界市場2018-2022] (Global Retinal Drugs Market 2018-2022 / IRTNTR22469)販売に関する免責事項
[網膜用治療薬の世界市場2018-2022] (Global Retinal Drugs Market 2018-2022 / IRTNTR22469)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆